Dr. Reddy's debuts generic DDAVP

Dr. Reddy’s is launching desmopressin acetate injection, in a dosage strength of 4 mcg/mL. The product is the generic of Ferring’s DDAVP (desmopressin acetate) injection.

“The launch of Desmopressin injection demonstrates a strong, growing collaboration with SunGen Pharma. We look forward to future opportunities with this company,” Marc Kikuchi, Dr. Reddy’s CEO, North America generics said. 

Dr. Reddy’s product is available in a carton of 10 1 mL single-dose ampules.

"We are pleased to be working with Dr. Reddy’s for this launch. The launch of Desmopressin demonstrates our strong development capabilities. We look forward to collaborating further to bring specialty pharmaceutical drugs to the markets around the world," said Isaac Liu, SunGen Co-CEO.

The DDAVP (desmopressin acetate) injection brand and generic have a market value of approximately $20.9 million for the most recent 12 months ending in March 2020, according to IQVIA.